Tricyclic thienopyridine-pyrimidones/thienopyrimidine-pyrimidones as orally efficacious mGluR1 antagonists for neuropathic pain

Bioorg Med Chem Lett. 2009 Jun 15;19(12):3199-203. doi: 10.1016/j.bmcl.2009.04.104. Epub 2009 May 3.

Abstract

Introduction of small unsaturated alkylamino groups at the 4-position of the A-ring of the tricyclic framework (triazafluorenone) afforded extremely potent and selective mGluR1 antagonists with desirable properties. Compounds 11q and 11s are active in the SNL pain model with ED(50)s 3.3 and 6.4 mg/kg respectively. Metabolic outcome of propargyl amino moiety was studied.

MeSH terms

  • Administration, Oral
  • Animals
  • Dose-Response Relationship, Drug
  • Heterocyclic Compounds, 3-Ring / chemistry
  • Heterocyclic Compounds, 3-Ring / pharmacology
  • Humans
  • Inhibitory Concentration 50
  • Neuralgia / drug therapy*
  • Pyridines / chemistry*
  • Pyridines / pharmacology
  • Pyrimidines / chemistry*
  • Pyrimidines / pharmacology
  • Rats
  • Receptors, Metabotropic Glutamate / antagonists & inhibitors*
  • Structure-Activity Relationship

Substances

  • Heterocyclic Compounds, 3-Ring
  • Pyridines
  • Pyrimidines
  • Receptors, Metabotropic Glutamate
  • metabotropic glutamate receptor type 1
  • thienopyridine
  • thienopyrimidine